Moderna Doubles on Cancer Vaccine's 'Landmark Win,' Merck Hits Record High

Moderna shares soared on Wednesday, doubling in value after positive results from a late-stage trial of its cancer vaccine, developed in partnership with Merck. The vaccine showed promising outcomes in melanoma patients, driving a significant surge in Moderna's stock price. This success also helped Merck reach a record high in its stock value. The news was hailed as a "landmark win" for Moderna, underscoring the significance and impact of this development in the medical and pharmaceutical sector.